文献速递慢性肾脏病血液净化与透析

目标试验模拟:GLP-1受体激动剂、SGLT2抑制剂与DPP-4抑制剂对肾脏结局的预防作用

Target Trial Emulation: Glucagon-Like Peptide-1 Receptor Agonist, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors for Kidney Outcome Prevention.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-03-26

该研究采用目标试验模拟方法,在退伍军人糖尿病队列中比较加用GLP-1受体激动剂、SGLT2抑制剂或DPP-4抑制剂的肾脏结局。经倾向评分加权后,GLP-1受体激动剂和SGLT2抑制剂相比DPP-4抑制剂均与复合肾脏事件及死亡风险降低相关,且亚组结果一致。

要点

  • GLP-1受体激动剂和SGLT2抑制剂均与肾脏事件及死亡复合结局风险降低相关。
  • SGLT2抑制剂对肾脏事件的保护关联幅度大于GLP-1受体激动剂。
  • 保护关联在老年、短疗程等亚组中一致,支持老年人群一级预防价值。

核心结论

  • 在退伍军人糖尿病患者中,加用GLP-1受体激动剂或SGLT2抑制剂相比DPP-4抑制剂与复合肾脏事件及死亡风险降低相关,且各亚组结果相似。

研究设计与样本

  • 回顾性队列目标试验模拟,纳入新加用GLP-1受体激动剂、SGLT2抑制剂或DPP-4抑制剂的退伍军人糖尿病患者。
  • 经倾向评分加权后,GLP-1受体激动剂组42,684例、SGLT2抑制剂组44,198例、DPP-4抑制剂组44,213例。
  • 中位年龄69岁,糖尿病病程10.6年(6.8-15.2),eGFR 75 ml/min per 1.73 m²(58-92)。

主要发现

  • 每1000人年事件率:GLP-1受体激动剂34.6(33.3-36.0)、SGLT2抑制剂29.0(27.8-30.3)、DPP-4抑制剂47.4(46.0-48.9)。
  • 复合肾脏事件及死亡风险:GLP-1受体激动剂 vs DPP-4抑制剂 HR 0.70(0.67-0.74);SGLT2抑制剂 vs DPP-4抑制剂 HR 0.65(0.61-0.68)。
  • 肾脏事件病因特异风险:GLP-1受体激动剂 HR 0.72(0.65-0.80);SGLT2抑制剂 HR 0.48(0.43-0.55)。

临床怎么用

  • 在老年糖尿病患者中,加用GLP-1受体激动剂或SGLT2抑制剂可能有助于降低肾脏事件及死亡风险,尤适用于一级预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Unknown if addition of newer diabetes medications is associated with kidney disease among older patients who were under recruited in clinical trials. In this target trial emulation, we report a protective association for kidney events and death for both glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor, compared with dipeptidyl peptidase-4 inhibitor. The association of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor on kidney disease extended across multiple subgroups including short duration of use and in the older population. BACKGROUND: A trial emulation approach evaluated kidney outcomes for addition of three diabetes medications among Veterans, including older Veterans underrepresented in trials. METHODS: A retrospective cohort of Veterans with diabetes who were new users adding glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter 2 inhibitors (SGLT2is), or dipeptidyl peptidase-4 inhibitors (DPP4is). Each group was followed until a composite of death or kidney event defined as a 50% decline in eGFR, kidney failure (transplant or dialysis) or censored for nonpersistence of drug class, loss of follow-up, and study end. The primary analysis used propensity score weights to compare the hazard of the composite outcome. The secondary analysis considered cause-specific hazard of kidney events with death as censoring. An Aalen-Johansen plot displayed individual outcomes of kidney event or death as a competing risk. Subgroup analyses evaluated Veterans by duration of use, age, eGFR, and urine protein. RESULTS: After propensity score weighting, the cohort included 42,684 GLP-1 RA, 44,198 SGLT2i, and 44,213 DPP4i episodes. The median age was 69 years, diabetes duration was 10.6 years (6.8-15.2), and eGFR was 75 ml/min per 1.73 m 2 (58-92). Event rates per 1000 person-years were 34.6 (33.3-36.0) versus 29.0 (27.8-30.3) versus 47.4 (46.0-48.9) for GLP-1 RA, SGLT2i, and DPP4i, respectively. There was a protective association for composite of kidney event and death for GLP-1 RA, hazard ratio (HR) 0.70 (0.67 to 0.74), and SGLT2i users (HR, 0.65 [0.61 to 0.68]) versus DPP4i. The results were similar for the cause-specific hazard of kidney event alone GLP-1 RA (HR, 0.72 [0.65 to 0.80]) and SGLT2i (HR, 0.48 [0.43 to 0.55]) and for subgroups. CONCLUSIONS: GLP-1 RA and SGLT2i as add-on diabetes treatment were associated with lower composite and individual outcomes of kidney event and death. The association was similar across subgroups highlighting the value in primary prevention among older populations.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Hung A, Beck C, Greevy RA, et al. Target Trial Emulation: Glucagon-Like Peptide-1 Receptor Agonist, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors for Kidney Outcome Prevention. Clin J Am Soc Nephrol. 2026. PMID: 41885954. doi:10.2215/CJN.0000001033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。